Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research. Over 2000 research labs worldwide (about 30% of global market share) and 100 hospitals have adopted Strand's genomics solutions today. These include leading clinical research, pharmaceutical and biotechnology organizations. With a highly skilled interdisciplinary workforce of more than 200 computer and life scientists, Strand has set up three clinical and translational research laboratories in Bangalore that are enabled with cutting-edge Next Generation Sequencing (NGS) technologies. Strand is a portfolio company of Biomark Capital Partners, a San Francisco based global fund for health and life sciences. By enabling DNA sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing personalized medicine to the world. For more information, please visit www.strandls.com